Back to Search Start Over

Skin microbiome and its association with host cofactors in determining atopic dermatitis severity.

Authors :
Rauer, Luise
Reiger, Matthias
Bhattacharyya, Madhumita
Brunner, Patrick M.
Krueger, James G.
Guttman-Yassky, Emma
Traidl-Hoffmann, Claudia
Neumann, Avidan U.
Source :
Journal of the European Academy of Dermatology & Venereology. Apr2023, Vol. 37 Issue 4, p772-782. 11p.
Publication Year :
2023

Abstract

Background: Atopic dermatitis (AD) is a heterogeneous, chronic inflammatory skin disease linked to skin microbiome dysbiosis with reduced bacterial diversity and el)evated relative abundance of Staphylococcus aureus (S. aureus). Objectives: We aimed to characterize the yet incompletely understood association between the skin microbiome and patients' demographic and clinical cofactors in relation to AD severity. Methods: The skin microbiome in 48 adult moderate-to-severe AD patients was investigated using next-generation deep sequencing (16S rRNA gene, V1–V3 re)gion) followed by denoising (DADA2) to obtain amplicon sequence variant (ASV) composition. Results: In lesional skin, AD severity was associated with S. aureus relative abun)dance (rS = 0.53, p<0.001) and slightly better with the microbiome diversity measure Evenness (rS = −0.58, p<0.001), but not with Richness. Multiple regression confirmed the association of AD severity with microbiome diversity, including Shannon (in le)sional skin, p<0.001), Evenness (in non-lesional skin, p = 0.015) or S. aureus relative abundance (p<0.012), and with patient's IgE levels (p<0.001), race (p<0.032), age (p<0.034) and sex (p = 0.012). The lesional model explained 62% of the variation in AD severity, and the non-lesional model 50% of the variation. Conclusions: Our results specify the frequently reported “reduced diversity” of the AD-related skin microbiome to reduced Evenness, which was in turn mainly driven by S. aureus relative abundance, rather than to a reduced microbiome Richness. Finding associations between AD severity, the skin microbiome and patient's cofac)tors is a key aspect in developing new personalized AD treatments, particularly those targeting the AD microbiome. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09269959
Volume :
37
Issue :
4
Database :
Academic Search Index
Journal :
Journal of the European Academy of Dermatology & Venereology
Publication Type :
Academic Journal
Accession number :
163238013
Full Text :
https://doi.org/10.1111/jdv.18776